Company Overview
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Why Investors Should Care
Generates a return on equity of 71.3%, reflecting efficient use of shareholder capital.
Recent Developments
- Trailing 12 Months Year-on-year growth — earnings -193.4%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -193.37% |
Stock Price Performance
| 1 Year: | -70.62% |
| 6 Months: | -78.04% |
| 3 Months: | -67.81% |
| 1 Month: | -15.16% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.33 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 71.3%.
CONS
- Trading 83.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AEON AEON Biopharma, Inc. PHARMA | 0.24 | -0.05 | $11.97M | 0.00% | - | 71.28% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.95M | 4.32M | 2.53M | 5.50M | 5.94M |
| Operating Income | -200.86K | -398.44K | -450.89K | -389.07K | -427.20K | -9.91M | -13.05M | -13.97M | -283.71M | -74.15M | 153.47M | -4.02M | - | -3.95M | -4.32M | -2.53M | -5.50M | -5.94M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.93M | -4.30M | -2.51M | -5.48M | -5.92M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.10M | -6.64M | -4.54M | -37.14M | -11.79M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Net Income | 6.32M | -4.03M | 5.66M | 2.77M | 1.87M | -10.44M | -17.64M | -15.38M | -297.71M | -118.02M | 164.11M | -6.17M | - | 9.10M | -6.64M | -4.54M | -37.14M | -11.79M |
| Diluted EPS | - | - | - | - | - | -0.08 | -0.13 | -0.11 | -8.01 | -227.87 | 304.00 | -11.24 | 3.75 | 2.28 | -0.60 | -0.39 | - | -0.29 |
| R&D Expense | - | - | - | - | - | 7.48M | 9.21M | 9.03M | 6.39M | 5.73M | 4.44M | 972.00K | - | 825.00K | 1.06M | 597.00K | - | 2.03M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 36.88M | 48.43M | - | 27.82M | 16.30M |
| Operating Income | -36.88M | -48.43M | - | -27.82M | -16.30M |
| EBITDA | -36.88M | -48.36M | - | -27.73M | -16.22M |
| Interest Expense | - | - | - | - | - |
| Pretax Income | -55.64M | -52.56M | - | 42.01M | -39.22M |
| Tax Provision | 0 | 0 | - | 0 | 0 |
| Net Income | -55.64M | -52.56M | - | 42.01M | -39.22M |
| Diluted EPS | -182.12 | -172.03 | - | 72.93 | -3.95 |
| R&D Expense | - | 34.75M | - | 14.18M | 4.09M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Jan 2023 | Jul 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | 81.00K | - | 10.78M | - | - | 6.84M | 3.14M | 5.56M |
| Current Assets | - | - | 9.84M | - | - | 6.22M | 1.59M | 3.40M |
| Cash & Equivalents | - | - | 9.75M | 31.20M | 31.20M | 5.16M | 13.00K | 3.01M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - |
| Total Liabilities | 59.59K | - | 281.19M | - | - | 159.89M | 31.71M | 60.59M |
| Current Liabilities | 59.59K | - | 82.57M | - | - | 13.05M | 14.15M | 6.90M |
| Long Term Debt | - | 70.76M | 60.43M | - | - | - | 11.69M | 34.60M |
| Total Debt | - | - | 131.79M | - | - | 278.00K | 12.96M | 35.74M |
| Total Equity | 21.41K | - | -287.50M | - | -310.82M | -153.04M | -28.57M | -55.03M |
| Shares Outstanding | - | - | 380.98K | - | - | 516.11K | 555.51K | 12.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -28.43M | -35.58M | -20.29M | -17.31M |
| Investing Cash Flow | -170.00K | -306.00K | 0 | -4.00K |
| Financing Cash Flow | 13.56M | 40.51M | 15.15M | 20.30M |
| Capital Expenditure | -170.00K | -306.00K | - | -4.00K |
| Free Cash Flow | -28.60M | -35.89M | -20.29M | -17.31M |
| Net Change in Cash | -15.04M | 4.62M | -5.14M | 2.99M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | 18.3% | - | -147.0% | 71.3% |
| ROCE % | - | 67.5% | - | 252.8% | 1,219.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Dauntless Investment Group, LLC | 25.04% | 12.49M | $3.03M |
| 2 | Geode Capital Management, LLC | 0.19% | 95.31K | $23.11K |
| 3 | Vanguard Capital Management LLC | 0.18% | 90.53K | $21.95K |
| 4 | Blue Owl Capital Holdings LP | 0.08% | 42.35K | $10.27K |
| 5 | Formidable Asset Management, Llc | 0.04% | 20.02K | $4.86K |
| 6 | Stonex Group Inc. | 0.04% | 18.95K | $4.60K |
| 7 | Vanguard Fiduciary Trust Co | 0.03% | 13.71K | $3.33K |
| 8 | LPL Financial LLC | 0.02% | 11.51K | $2.79K |
| 9 | Citigroup Inc. | 0.01% | 7.32K | $1.77K |
| 10 | UBS Group AG | 0.01% | 5.06K | $1.23K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AEON
AEON Biopharma Designates Former FDA Neuroscience Leader Paul Lee, M.D., Ph.D. as Acting Chief Regulatory Officer
- Former Deputy Director of the FDA’s Office of Neuroscience - Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-450 ALISO VIEJO, Calif.…
AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program - Upfront proceeds from financing provide …
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to…
AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding
$13.75 million underwritten public offering with up to an additional $29.6 million in potential proceeds tied to the cash exercise in full of the milestone warrants issued in the offeringIRVINE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AEO…
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society
IRVINE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achi…
AEON Biopharma Sets Annual Shareholder Meeting
- Annual Shareholder Meeting to be held at 10:00 am PT on June 17, 2026 - IRVINE, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450…
AEON — Frequently Asked Questions
What is the current share price of AEON Biopharma, Inc. (AEON)?
As of 2026-09-19 21:16 PDT, AEON Biopharma, Inc. (AEON) trades at $0.24 on NYSE American. Its 52-week range is $0.19 to $1.40.
What is the market capitalisation of AEON?
AEON Biopharma, Inc. (AEON) has a market capitalisation of $11.97M on NYSE American.
What is the P/E ratio of AEON?
AEON trades at a trailing price-to-earnings (P/E) ratio of -0.05. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.40.
What is the return on equity (ROE) of AEON?
AEON has a return on equity (ROE) of 71.28%.
Is AEON a good stock to buy?
This page provides a data-driven analysis of AEON Biopharma, Inc. (AEON), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.